ArticleInfluenza and other respiratory viruses2025
Evaluating Bacillus Calmette-Guérin Polysaccharide Nucleic Acid as an Adjuvant for Influenza Vaccines in Mice.
Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundTo enhance influenza vaccine efficacy, it is essential to investigate new adjuvants that are both safe and effective. In a recent study utilizing a mouse model, Bacillus Calmette-Guérin polysaccharide nucleic acid (BCG-PSN) emerged as a promising candidate vaccine adjuvant.
methodsThis study evaluated the immunomodulatory effects of BCG-PSN on influenza vaccines hemagglutinin antigen and aluminum adjuvant as controls. Mice were immunized with H1N1 antigen and adjuvants, and serum antibody levels were measured using hemagglutination inhibition, enzyme-linked immunosorbent assay, and microneutralization assays. Flow cytometry and enzyme-linked immunospot assays assessed T cell phenotypes and cytokine expression. The protective effects were tested through challenge experiments, and the adjuvants were further evaluated in a quadrivalent seasonal influenza vaccine.
resultsBCG-PSN adjuvant exhibited favorable safety profiles and demonstrated an ability to elevate total antibody titers, particularly enhancing neutralizing antibody production when co-administered with the H1N1 antigen. BCG-PSN increased cytokine levels and the proportion of CD8+ T lymphocytes, indicating its capacity to enhance cellular immunity. Upon viral challenge in mice, BCG-PSN mitigated the production of inflammatory factors and reduced lung pathology, effectively protecting the mice. Furthermore, BCG-PSN displayed heightened immunogenicity against a mixture of four antigens.
conclusionsBCG-PSN is a reliable and efficient adjuvant for influenza vaccines, holding promise for enhancing vaccine efficacy and increasing immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.